Abiomed pivoted from an artificial heart to the tiny Impella pump behind it

Through the 1990s Abiomed chased the world's first fully implantable artificial heart, a goal that consumed money and promise. Its breakthrough came when it bought a small German device called Impella in 2005.

Impella is a tiny pump inserted through the femoral artery in minutes to support a failing heart, shifting Abiomed's mission from replacing hearts to recovering them. It reduced the need for open-heart surgery in certain heart-attack cases.

Abiomed spent the 2008 crisis and the years after expanding Impella's clinical evidence and indications. BCG ranked it the second-best company of the 25 that most outperformed the S&P Global 1200 from 2008 to 2019.

Ranked second among BCG's post-2008 outperformers; Impella became its dominant product and revenue rose every year after the 2005 acquisition.

Bought the Impella pump in 2005, a deliberate shift from heart replacement to recovery.

Built clinical evidence and new indications through the downturn instead of cutting.

A smaller, higher-probability device beat a moonshot artificial heart on commercial odds.

A strategic pivot that swaps an impossible ambition for a smaller, higher-probability niche can compound for a decade.

Impella grew to account for the vast majority of Abiomed's revenue, and the company expanded from single procedures into a platform of heart-recovery products, adding more indications and devices through the 2010s.